Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Iceland based Actavis Group has received FDA approval for irinotecan hydrochloride injection, a cancer drug.
Subscribe to our email newsletter
Irinotecan hydrochloride Injection, the generic equivalent to Pfizer’s Camptosar, is used to treat patients with metastatic carcinoma of the colon or rectum.
Doug Boothe, executive vice president of US commercial and administration, said: “The launch of Irinotecan marks the expansion of company’s US portfolio into the injectable pharmaceuticals arena. Actavis has set its sights firmly on the hospital sector and currently has around 300 pending applications worldwide for injectable medicines.”